Release date: 2008-10-13 China leading manufacturers and suppliers of Medical Adhesive Tape,Medical Hypoallergenic Tape, and we are specialize in Medical Breathable Tape , Medical Tape , etc. Medical Adhesive Tape,Medical Hypoallergenic Tape,Medical Breathable Tape ,Medical Tape Surgimed Medical Supplies Co.,Ltd , https://www.surgimedcn.com
Siemens Medical announced the results of early research on new imaging biomarkers for hypoxic tumors, turning personalized medicine from a dream into a reality. The study was conducted in collaboration with Dr. Jian Q. (Michael) Yu and the Fox Chase Cancer Center in Philadelphia, and the results were presented at the Global Molecular Imaging Conference in Nice, France. This imaging biomarker will be exclusively distributed worldwide by PETNET Solutions, a wholly owned subsidiary of Siemens.
Safety studies have shown that the new imaging biomarker HX4 developed by Siemens Molecular Imaging Biomarker Research can be safely applied to human positron emission tomography (PET) imaging. The study included initial human data for biomarker biomarkers, radiation dose levels for normal volunteers, and optimal patient PET imaging parameters. The results of the study showed that the compound remained stable after 145 minutes of label injection. Biomarkers can be safely excreted through the urinary system, and the dose accumulation of major organs is very low.
"The imaging of hypoxic tumors can greatly change the disease management of cancer patients. The predictive value of this information can effectively improve the quality of life of cancer patients, and bring about possible personalized and efficient treatment." Siemens Molecular Imaging Biomarker Research Company According to Hartmuth Kolb, Vice President, “Siemens is working to develop a new approach by combining new imaging biomarkers with molecular imaging technology to show the progress of the disease so that healthcare providers can detect the disease as soon as possible and strengthen the disease. Management."
Hypoxic cells are a clinical challenge and they are generally less responsive to standard treatments. Hypoxic probes are a very useful tool for oncologists. The development of imaging biomarkers that selectively identify hypoxic tumor cells can help radiologists design treatments to efficiently manage disease.
The Siemens Molecular Imaging Biomarker Research Company in Los Angeles specializes in the research and development of new imaging biomarkers to facilitate the development of molecular diagnostics in vivo. The company's scientists are committed to the research of new contrast agents and their clinical applications, with a view to developing new contrast agents for the market in the next 5 to 10 years. The organization's research and development focuses on oncology and neurology, and includes areas such as inflammation and microfluidics/nanotechnology research.
PETNET Solutions operates the largest network of PET radiopharmaceuticals consisting of 50 radiopharmaceutical production and sales centers, providing PET radiopharmaceuticals to hospitals, clinics and PET imaging research institutions. Currently, PETNET Solutions is expanding its radiopharmaceutical network to promote the worldwide use of PET. With the development of molecular imaging technology, PETNET Solutions continues to provide medical service providers, referral doctors and patients with products and services that enhance the value of PET. PETNET Solutions advances the development of PET science through premium PET tracers. ——Shanghai Medical Device Industry Association